DAIICHI SANKYO, INC.

Lobbying for DAIICHI SANKYO INC

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Expenses

$370,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications

Taxation/Internal Revenue Code

Discussions regarding tax reform and tariffs

Medicare/Medicaid

Issues related to the Medicare Drug Price Negotiation Program Issues regarding the GLOBE model

Issues related to intellectual property rights

Bills named in this filing 3

H.R. 946
ORPHAN Cures Act
H.R. 2319
Women and Lung Cancer Research and Preventive Services Act of 2025
H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.